Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 12 clinical trials
None
Acute Maternal Hyperoxygenation in CHD

Congenital heart disease (CHD) is predominantly detected before birth. Using echocardiography and MRI, this study will determine whether acute exposure to maternal hyperoxygenation (MH) leads to measurable increases in fetal cerebral oxygenation from baseline in fetuses with CHD. The study aims to determine whether MH could be used as a …

tetralogy of fallot
septal defect
hypoplastic left heart syndrome
hlhs
ventricular septal defect
  • 6 views
  • 22 Aug, 2021
  • 1 location
None
Trial of Maternal Oxygen for Fetal Left Heart Hypoplasia

The purpose of this study is to determine if maternal hyperoxygenation is an effective treatment for fetal left heart hypoplasia versus room air (placebo). This will be determined by measuring how well a baby's heart valves and their surrounding tissue are growing and functioning. In addition the investigators will examine …

  • 0 views
  • 26 Jan, 2021
  • 1 location
None
Optical Tissue Identification for Myocardial Architecture

The goal of this study is to test the hypothesis that fiberoptic confocal microscopy (FCM) imaging during repair of common congenital heart defects is a useful adjunct for avoidance of conduction abnormalities.

  • 0 views
  • 25 Jun, 2021
None
Targeting Normoxia in Neonates With Cyanotic Congenital Heart Disease in the Intra-operative and Immediate Post-operative Period

This clinical trial is studying the use of different levels of oxygen exposure during and after cardiopulmonary bypass in eligible infants to learn about its safety during heart surgery. In addition to having the various doses of oxygen, patients that participate will also have blood samples, ultrasounds of the head, …

  • 0 views
  • 21 Oct, 2021
  • 1 location
None
Extended Criteria For Fetal Myelomeningocele Repair

; abnormality must be minor, not increasing the risk of prematurity. For example cleft lip and palate, minor ventricular septal defect, pyelectasis. Maternal Rh alloimmunization. Must have a low level

repair of myelomeningocele
diabetes
prematurity
cleft lip
amniocentesis
  • 24 views
  • 16 Apr, 2021
  • 2 locations
None
A Multicenter International Follow-up Study to Monitor the Efficacy and Safety of the Occlutech PmVSD Occluder in Patients With Perimembranous Ventricular Septal Defects

The objective of this registry is to gain more insight on the clinical use of the Occlutech perimembranous VSD occluder.

  • 6 views
  • 27 Jan, 2021
  • 8 locations
None
French Observatory of Congenital Ventricular Septal Defect With Pulmonary Overload

Ventricular septal defects (VSD) are the most common cardiac congenital heart defect (about 1/3 of patients with congenital heart disease). VSD management is related to hemodynamics and anatomical localization and the occurrence of complications. Small perimembranous VSD without pulmonary hypertension and without significant left to right shunting are tolerated, whereas …

ventricular septal defect
congenital heart defects
hypertension
septal defect
  • 9 views
  • 23 Jan, 2021
  • 3 locations
None
  • 0 views
  • 28 Nov, 2021
  • 4 locations
None
Aortic Regurgitation After Surgical Repair of Outlet-Type Ventricular Septal Defect

The major risk factors of aortic valve replacement in three outlet types VSD after surgical repair were the severity of preoperative AR and older operation age. For those patients with less than moderate degree AR preoperatively, AR progressed rarely and all in those with aortic valvar and subvalvar anomalies.

ventricular septal defect
aortic valve replacement
  • 13 views
  • 07 Nov, 2020
None
The AMPLATZER Post-infarct Muscular VSD Occluder Humanitarian Device Exemption (H070005) The AMPLATZER Post-infarct Muscular VSD Occluder Humanitarian Device Exemption (H070005) Post Approval Study

FDA issued a Humanitarian Device Exemption (HDE) approval order for the AMPLATZER PIVSD Occluder (H070005) on January 10, 2017. The Conditions of Approval require that SJM conduct a post approval study to evaluate the safety and probable benefit of the AMPLATZER PIVSD Occluder.

  • 181 views
  • 16 Nov, 2021
  • 23 locations